An iron delivery pathway mediated by a lipocalin J Yang, D Goetz, JY Li, W Wang, K Mori, D Setlik, T Du, ... Molecular cell 10 (5), 1045-1056, 2002 | 922 | 2002 |
Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects JE Allen, G Krigsfeld, PA Mayes, L Patel, DT Dicker, AS Patel, NG Dolloff, ... Science translational medicine 5 (171), 171ra17-171ra17, 2013 | 328 | 2013 |
The myc–mir-17∼ 92 axis blunts TGFβ signaling and production of multiple TGFβ-dependent antiangiogenic factors M Dews, JL Fox, S Hultine, P Sundaram, W Wang, YY Liu, E Furth, ... Cancer research, 0008-5472. CAN-10-2412, 2010 | 322 | 2010 |
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death MS Ricci, SH Kim, K Ogi, JP Plastaras, J Ling, W Wang, Z Jin, YY Liu, ... Cancer cell 12 (1), 66-80, 2007 | 300 | 2007 |
The α1-6-fucosyltransferase gene and its biological significance E Miyoshi, K Noda, Y Yamaguchi, S Inoue, Y Ikeda, W Wang, JH Ko, ... Biochimica et Biophysica Acta (BBA)-General Subjects 1473 (1), 9-20, 1999 | 287 | 1999 |
Critical role for Daxx in regulating Mdm2 J Tang, LK Qu, J Zhang, W Wang, JS Michaelson, YY Degenhardt, ... Nature cell biology 8 (8), 855, 2006 | 280 | 2006 |
Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth P Fei, W Wang, S Kim, S Wang, TF Burns, JK Sax, M Buzzai, DT Dicker, ... Cancer cell 6 (6), 597-609, 2004 | 276 | 2004 |
Current strategies to target p53 in cancer F Chen, W Wang, WS El-Deiry Biochemical pharmacology 80 (5), 724-730, 2010 | 215 | 2010 |
Altered glycosylation of serum transferrin of patients with hepatocellular carcinoma E Miyoshi, K Noda, Y Yamaguchi, S Inoue, Y Ikeda, W Wang, JH Ko, ... J Biol Chem 264 (5), 2415-23, 1999 | 213* | 1999 |
Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding W Wang, R Takimoto, F Rastinejad, WS El-Deiry Molecular and cellular biology 23 (6), 2171-2181, 2003 | 189 | 2003 |
The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis R Takimoto, W Wang, DT Dicker, F Rastinejad, J Lyssikatos, WS El-Deiry Cancer biology & therapy 1 (1), 47-55, 2002 | 169 | 2002 |
Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts W Wang, SH Kim, WS El-Deiry Proceedings of the National Academy of Sciences 103 (29), 11003-11008, 2006 | 154 | 2006 |
Restoration of p53 to limit tumor growth W Wang, WS El-Deiry Current opinion in oncology 20 (1), 90-96, 2008 | 152 | 2008 |
TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death K Kuribayashi, G Krigsfeld, W Wang, J Xu, PA Mayes, DT Dicker, GS Wu, ... Cancer biology & therapy 7 (12), 2034-2038, 2008 | 121 | 2008 |
CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation W Yang, LM Rozan, ER McDonald, A Navaraj, JJ Liu, EM Matthew, ... Journal of Biological Chemistry 282 (5), 3273-3281, 2007 | 109 | 2007 |
Restoring p53-dependent tumor suppression W Wang, F Rastinejad, WS El-Deiry Cancer biology & therapy 2 (sup1), 54-62, 2003 | 108 | 2003 |
Acridine derivatives activate p53 and induce tumor cell death through Bax W Wang, WC Ho, DT Dicker, C MacKinnon, JD Winkler, R Marmorstein, ... Cancer biology & therapy 4 (8), 893-898, 2005 | 97 | 2005 |
Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model W Wang, WS El-Deiry Cancer biology & therapy 2 (2), 196-202, 2003 | 94 | 2003 |
Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: a comparative study M Yin, W Wang, JJ Drabick, HA Harold BMC cancer 17 (1), 295, 2017 | 86 | 2017 |
Fidelity for the quantum evolution of a Bose-Einstein condensate J Liu, W Wang, C Zhang, Q Niu, B Li Physical Review A 72 (6), 063623, 2005 | 73 | 2005 |